Clinical trial
A Phase 2 Proof-of-Concept Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Active Treatment Extension Period to Assess the Safety and Efficacy of Seladelpar and Cilofexor in Combination for Primary Biliary Cholangitis
NCT07841977 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Proof-of-Concept Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Active Treatment Extension Period to Assess the Safety and Efficacy of Seladelpar and Cilofexor in Combination for Primary Biliary Cholangitis
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- June 30, 2034
- Enrollment
- 132 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
primary biliary cholangitis